Skip to main content

Advertisement

SpringerLink
Log in

The epidermal growth factor receptor as a target for gastrointestinal cancer therapy

  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

The epidermal growth factor receptor (EGFR) is a member of the family of transmem-brane protein kinase receptors known as the erbB or HER receptor family. When activated, EGFR phosphorylates and activates other intracellular proteins that affect cell signaling pathways, cellular proliferation, control of apoptosis and angiogenesis. EGFR signaling is best thought of as a network of activating and inactivating proteins with EGFR as the entry point into the network. EGFR overexpression occurs in most GI malignancies and while data are not entirely consistent, EGFR overexpression often confers a poor prognosis in those GI malignancies that have been studied. It often correlates with poorly differentiated histology, more advanced stage and other known poor prognostic markers. The EGFR is a tempting target because of its presence and overexpression on so many tumor types. However, downstream of the EGFR are several proteins that may be activated without EGFR thus allowing blockade to be overcome. Therefore, while blocking the activity of the EGFR protein appears to be a promising anticancer strategy, a simplistic strategy of blocking only EGFR is likely to only impact a minority of patients. It is time for the laboratory and clinical researchers to work closely together to develop this treatment strategy, moving back and forth from clini-cal to laboratory to best understand how to block this network effectively enough to produce a broader antitumor effect. While multiple methods of targeting the EGFR pathway are under development, including the inhibition of downstream proteins, only two modalities have entered clinical trials in GI malignancies: small molecule inhibitors of the intracellular kinase domain of EGFR and antibodies designed to block the extracellular ligand-binding domain of EGFR. EGFR inhibitors are still experimental in every GI malignancy with the notable exception of cetuximab that is approved for second or third-line therapy of metastatic colorectal cancer, used either alone or in combination with irinotecan (Camptosar, Kalamazoo, Mich). Data on clinical applications of these agents in GI malignancies will be the focus of this paper.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Yarden Y, Sliwkowski MX: Untangling the ErbB signal-ling network. Nat Rev Mol Cell Biol 2001, 2:127–137.

    Article  PubMed  CAS  Google Scholar 

  2. Arteaga CL: Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia. Semin Oncol 2002, 29:3–9. This article is chosen as a key reference for review of the mech-anisms and basics of the EGFR signaling pathway.

    PubMed  CAS  Google Scholar 

  3. Lichtner RB, Menrad A, Sommer A, et al.: Signaling-inac-tive epidermal growth factor receptor/ligand complexes in intact carcinoma cells by quinazoline tyrosine kinase inhibitors. Cancer Res 2001, 61:5790–5795.

    PubMed  CAS  Google Scholar 

  4. Jemal A, Tiwari RC, Murray T, et al.: Cancer Statistics 2004. CA Cancer J Clin 2004, 54:8–29.

    Article  PubMed  Google Scholar 

  5. Gotoh M, Kawabe S, Takiuchi H, et al.: EGFR and cyclin D1 are possible predictors of sensitivity to chemoradiotherapy (CRT) for esophageal squamous cell carcinoma (SCC) [abstract]. Proc Am Soc Clin Oncol 2002, 21:164a.

    Google Scholar 

  6. Wilkinson NW, Smiley S, Roukhadze E, et al.: Epidermal growth factor receptor (EGFR) expression correlates with histologic grade in adenocarcinoma of the esophagus. J Gastrointest Surg 2004, 8:448–453.

    Article  PubMed  Google Scholar 

  7. Gibson MK, Abraham S, Wu T-T, et al.: Epidermal growth factor receptor, p53 mutation and pathologic response predict survival in patients with locally advanced esophageal cancer treated with preoperative chemoradiotherapy [abstract]. Clin Cancer Res 2003, 9(17):6461–6468.

    PubMed  CAS  Google Scholar 

  8. Song HS, Kim IH, Sohn SS, et al.: Prognostic signifi-cance of p53, Rb, EGFR, and c-erbB2 genes in cura-tively resected gastric cancer [abstract]. Proc Am Soc Clin Oncol 2003, 22:263.

    Google Scholar 

  9. Kopp R, Ruge M, Rothbauer E, et al.: Impact of epider-mal growth factor (EGF) radioreceptor analysis on long-term survival of gastric cancer patients. Antican-cer Res 2002, 22:1161–1167.

    CAS  Google Scholar 

  10. Garcia I, Vizoso F, Martin A, et al.: Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer. Ann Surg Oncol 2003, 10:234–241.

    Article  PubMed  CAS  Google Scholar 

  11. Malecka-Panas E, Fligiel SE, Relan NK, et al.: Azoxymethane enhances ligand-induced activation of EGF receptor tyrosine kinase in the colonic mucosa of rats. Carcinogenesis 1996, 17:233–237.

    Article  PubMed  CAS  Google Scholar 

  12. Roberts RB, Min L, Washington MK, et al.: Importance of epidermal growth factor receptor signaling in establishment of adenomas and maintenance of carci-nomas during intestinal tumorigenesis, Proc Natl Acad Sci U SA 2002, 99:1521–1526.

    Article  CAS  Google Scholar 

  13. Brunton VG, Ozanne BW, Paraskeva C, et al.: A role for epidermal growth factor receptor, c-Src and focal adhesion kinase in an in vitro model for the progres-sion of colon cancer. Oncogene 1997, 14:283–293.

    Article  PubMed  CAS  Google Scholar 

  14. Messa C, Russo F, Caruso, MG, et al.: EGF, TGF-alpha, and EGF-R in human colorectal adenocarcinoma. Acta Oncol 1998, 37:285–289.

    Article  PubMed  CAS  Google Scholar 

  15. Kluftinger AM, Robinson BW, Quenville NF, et al.: Cor-relation of epidermal growth factor receptor and c-erbB2 oncogene product to known prognostic indica-tors of colorectal cancer. Surg Oncol 1992, 1:97–105.

    Article  PubMed  CAS  Google Scholar 

  16. Steele RJ, Kelly P, Ellul B, et al.: Epidermal growth factor receptor expression in colorectal cancer. Br J Surg 1990, 77:1352–1354.

    Article  PubMed  CAS  Google Scholar 

  17. Koretz K, Schlag P, Moller P, et al.: Expression of epider-mal growth factor receptor in normal colorectal mucosa, adenoma, and carcinoma. Virchows Arch A Pathol Anat Histopathol 1990, 416:343–349.

    Article  PubMed  CAS  Google Scholar 

  18. Mayer A, Takimoto M, Fritz E, et al.: The prognostic sig-nificance of proliferating cell nuclear antigen, epider-mal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer 1993, 71:2454–2460.

    Article  PubMed  CAS  Google Scholar 

  19. McKay JA, Murray LJ, Curran S, et al.: Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases. Eur J Cancer 2002, 38:2258–2264.

    Article  PubMed  CAS  Google Scholar 

  20. Chang, SA, Chang, AY, Putti TC, et al.: Clinical and pathological correlations of epidermal growth factor receptor in patients with hepatoma [abstract]. Proc Am Soc Clin Oncol 2002, 21:145a.

    Google Scholar 

  21. Amador ML, Oppenheimer D, Maitra A, et al.: Genetic-based rational combination of ZD1839 and CI-1040 in biliary tract carcinoma [abstract]. Proc Am Soc Clin Oncol 2004, 125.

  22. Gibbs JF, Sreekumar B, Hylander B, et al.: Low Incidence of EGFR and Her2/neu positivity in pancreatic cancer [abstract]. Proc Am Soc Clin Oncol 2004, 134.

  23. Abbruzzese, JL, Rosenberg A, Xiong, Q, et al.: Phase II study of anti-epidermal growth factor receptor (EGFR) antibody cetuximab (IMC-C225) in combi-nation with gemcitabine in patients with advanced pancreatic cancer [abstract]. Proc Am Soc Clin Oncol 2001, 20:130a.

    Google Scholar 

  24. Uegaki K, Nio Y, Inoue Y, et al.: Clinicopathological sig-nificance of epidermal growth factor and its receptor in human pancreatic cancer. Anticancer Res 1997, 17:3841–3847.

    PubMed  CAS  Google Scholar 

  25. Buchsbaum DJ, Bonner JA, Grizzle WE, et al.: Treatment of pancreatic xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation. Int J Radiat Oncol Biol Phys 2002, 54:1180–1193.

    Article  PubMed  CAS  Google Scholar 

  26. Radovich, D, Kelsen, D, Shah M, et al.: OSI-774 in advanced esophageal cancer: a phase II study [abstract]. Proc Am Soc Clin Oncol 2004, 23:4077.

    Google Scholar 

  27. Van Groeningen C, Richel D, Giacconi G, et al.: Gefi-tinib phase-II study in second-line treatment of advanced esophageal cancer [abstract]. Proc Am Soc Clin Oncol 2004, 23:4022.

    Google Scholar 

  28. Rojo F, Tabernero J, Van Cutsem E, et al.: Pharmacody-namic studies of tumor biopsy specimens from patients with advanced gastric carcinoma undergoing treatment with gefitinib (ZD 1839) [abstract]. Proc Am Soc Clin Oncol 2003, 22:191.

    Google Scholar 

  29. Doi T, Koizumi W, Siena S, et al.: Efficacy, tolerability, and pharmacokinetics of gefitinib (ZD1839) in pre-treated patients with metastatic gastric cancer [abstract]. Proc Am Soc Clin Oncol 2003, 22:258.

    Google Scholar 

  30. Ciardiello F, Caputo R, Bianco R, et al.: Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000, 6:2053–2063.

    PubMed  CAS  Google Scholar 

  31. Braun AH, Dirsch O, Hilger R-A, et al.: Preclinical evalu-ation of the combination of epidermal growth factor inhibitor ZD1839 (Iressa) and irinotecan (SN-38) in human colon cancer cells. Proc Am Soc Clin Oncol 2002, 21:329–335.

    Google Scholar 

  32. Hammond LA, Figueroa J, Schwartzberg L, et al.: Feasi-bility and pharmacokinetic (PK) trial of ZD1839 (Iressa™), an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in combination with 5-fluorouracil (5FU) and leucovorin (LV) in patients with advanced colorectal cancer. Proc Am Soc Clin Oncol 2001, 20:544.

    Google Scholar 

  33. Cho CD, Fisher GA, Halsey JZ, et al.: A phase I study of ZD1839 (Iressa) in combination with oxaliplatin, 5- fluorouracil (5FU), and leucovorin (LV) in advanced solid malignancies. Proc Am Soc Clin Oncol 2002, 21:38.

    Google Scholar 

  34. Basche ML, Pierson AS, Holden SN, et al.: A phase I trial of ZD1839 (Z) with capecitabine (Cp) and celecoxib (Cel) in patients (pts) with advanced solid tumors. Proc Am Soc Clin Oncol 2003, 22:209–211.

    Google Scholar 

  35. Goss GD, Stewart DJ, Hirte H, et al.: Initial results of part 2 of a phase I/II pharmacokinetics (PK), pharma-codynamic (PD) and biological activity study of ZD1839 (Iressa): NCIC CTG IND.122. Proc Am Soc Clin Oncol 2002, 21:59.

    Google Scholar 

  36. Rothenberg ML, Lafleur B, Washington MK, et al.: Changes in epidermal growth factor receptor signal-ing in serum and tumor biopsies obtained from patients with progressive metastatic colorectal cancer MCRC treated with gefitinib (ZD 1839) Eastern Coop-erative Oncology Group study [abstract]. Proc Am Soc Clin Oncol 2004, 23:3000.

    Google Scholar 

  37. Oza AM, Townsley CA, Siu LL, et al.: Phase II study of erlotinib (OSI-774) in patients with metastatic col-orectal cancer. Proc Am Soc Clin Oncol 2003, 22:196.

    Google Scholar 

  38. Saltz L, Rubin M, Hochster H, et al.: Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epi-dermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 2001, 20:7.

    Google Scholar 

  39. Saltz L, Meropol NJ, Loehrer PJ, et al.: Phase II trial of cetuximab in patients with refractory colorectal can-cer that expresses the epidermal growth factor recep-tor. J Clin Oncol 2004, 22:1201–1208. This is an important publication for several reasons: this is the first peer-reviewed publication demonstrating antitumor effi-cacy in any GI malignancy for an EGFR inhibitor, it defines the frequency of EGRF positivity in a clinical population, and it confirms the toxicity profile of single-agent cetuximab in a clinical population.

    Article  PubMed  CAS  Google Scholar 

  40. Cunningham D, Humblet Y, Siena S, et al.: Cetuximab (C225) alone or in combination with irinotecan (CPT-11) in patients with epidermal growth factor receptor (EGFR)-positive, irinotecan-refractory meta-static colorectal cancer (MCRC). Proc Am Soc Clin Oncol 2003, 22:252.

    Google Scholar 

  41. Lenz HJ, Mayer RJ, Gold PJ, et al.: Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin [abstract]. Proc Am Soc Clin Oncol 2004, 23:3510.

    Google Scholar 

  42. Yang XD, Jia XC, Corvalan JR, et al.: Development of ABX-EGF, a fully human anti-EGF receptor mono-clonal antibody, for cancer therapy. Crit Rev Oncol Hematol 2001, 38:17–23.

    PubMed  CAS  Google Scholar 

  43. Meropol NJ, Berlin J, Hecht JR, et al.: Multicenter study of ABX-EGF monotherapy in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 2003, 22:256.

    Google Scholar 

  44. Philip PA, Geyer SM, Thomas JP, et al.: Tolerability of OSI-774 (Tarceva) in locally advanced or metastatic hepatocellular (HCC) and biliary (BILI) carcinomas: an interim report [abstract]. Proc Am Soc Clin Oncol 2003, 22:364.

    Google Scholar 

  45. Philip PA, Mahoney MR, Thomas JP, et al.: Phase II trial of OSI-774 in patients with hepatocellular and biliary cancer [abstract]. Gastro Cancers Symp 2004, 174.

  46. Morgan, JA, Bukowski, RM, Xiong, H, et al.: Preliminary report of a phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor (EGFR), given in combination with gemcitabine to patients with advanced pancreatic cancer [abstract]. Proc Am Soc Clin Oncol 2003, 22:197.

    Google Scholar 

  47. Lynch TJ, Bell DW, Sordella R, et al.: Activating muta-tions in the epidermal growth factor receptor underly-ing responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129–2139.

    Article  PubMed  CAS  Google Scholar 

  48. Zhang W, Yun J, Press OA, et al.: Association of cyclin D1 (CCND1) gene A870G polymorphism and clinical outcome of EGFR-positive metastatic colorectal cancer patients treated with epidermal growth factor receptor (EGFR) inhibitor cetuximab (C225) [abstract]. Proc Am Soc Clin Oncol 2004, 23:3518.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Vanderbilt University Medical Center, 777 Preston Research Building, 37232, Nashville, TN, USA

    Jordan D. Berlin MD

Authors
  1. Karen L. Tedesco MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Craig Lockhart MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jordan D. Berlin MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tedesco, K.L., Lockhart, A.C. & Berlin, J.D. The epidermal growth factor receptor as a target for gastrointestinal cancer therapy. Curr. Treat. Options in Oncol. 5, 393–403 (2004). https://doi.org/10.1007/s11864-004-0029-z

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-004-0029-z

Keywords

Search

Navigation